JScope
Start free trial
Home / Projects / Pharma & medical
R&D facilityPharma & medical

Seed revises plans for Konosu Research Center Building No.4 Phase II

Seed Co., Ltd.Konosu, SaitamaPublished
InvestmentNot disclosed
PhasePlanned
Start—
Completion—

Seed Co., a contact lens manufacturer, disclosed a partial change to the previously announced acquisition of fixed assets related to the second-phase construction of Building No. 4 at its Konosu Research Center. Specific revised terms were not detailed in the available text.

Project facts

Owner
Seed Co., Ltd.
Listing
7743 Tokyo
Facility
R&D facility
Sector
Pharma & medical
Location
Konosu, Saitama, Japan
Investment
Not disclosed
Announced
Jul 13, 2026

Figures and schedules are as announced by the company or the public body concerned; plans can change. Amounts that were not disclosed are recorded as not disclosed, never estimated.

Also in Saitama12 projects · ¥43.4B disclosedOn the map →

Acecook breaks ground on new ¥27bn Kanto plant in Kawagoe, SaitamaAcecook Co., Ltd.Under construction¥27BADEKA launches new Semiconductor Innovation Center in KukiADEKA CorporationCompleted¥12BMitsubishi Cable Industries completes new Kumagaya No. 2 plant for next-gen seal productsMitsubishi Cable Industries, Ltd.Completed¥4.4BYukiguni Factory to open Kinoko Mirai Lab R&D facility in KawaguchiYukiguni Factory Co., Ltd.Completedn/d

Latest in Pharma & medicalAll Pharma & medical →

Fujifilm to install ADC raw-material manufacturing equipment at Hirono plant

NewPharma & medicalFukushimaPlanned

Fujifilm will install payload and linker-payload manufacturing equipment, including reaction vessels, a filtration dryer and a preparative HPLC system, at the Hirono plant in Fukushima. The facility will also add a laboratory for process and analytical-method development, with operations scheduled to begin in 2028, enabling Fujifilm's one-stop domestic ADC CDMO service.

Shikoku Chuken to build new headquarters and research facility in Ayagawa

Pharma & medicalKagawaPlanned

Shikoku Chuken will build a new headquarters facility on land adjacent to its existing headquarters in Ayagawa, Kagawa. The facility will expand research and development using clinical specimens and testing data collected from across Shikoku, along with corporate planning, information processing and administrative functions; operations are scheduled to begin in January 2028.

Olympus completes new B Building at Nagano site for medical-device component production

Pharma & medicalNaganoCompleted¥18B

Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.

JGC completes Chugai Pharma's UT3 biopharmaceutical API facility in Utsunomiya

Pharma & medicalTochigiCompleted

JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.